ICF & Pharmaceutical Terminology
47 specialist terms used in Informed Consent Forms and pharmaceutical clinical trial documentation - reflecting the level of knowledge and expertise required in handling Pharma/ICF translations.
At Semantics Trans Pvt Ltd., we specialize in this field. Our pharmaceutical translators understand these terms not just linguistically, but in their full clinical and regulatory context.
Adverse Event (AE)
Any untoward medical occurrence in a participant, regardless of whether it is considered related to the drug.
Advocacy Groups
Advocacy groups and patient organizations support the needs of patients.
Arm / Cohort
A group of participants receiving specific treatment or a placebo.
Blinding / Masking
A technique where the participant and/or researchers do not know which treatment is being given to avoid bias.
Clear the BodyPlain English
Plain English alternative for "Metabolize."
Clinical Trial Sponsor
Clinical trial sponsors can be organizations or medical institutions, foundations, voluntary groups, pharmaceutical companies etc.
Comparator-Controlled
The investigational drug is compared with a drug that is already approved for use. This helps the trial team to see if the investigational drug could have benefits over drugs that are already approved.
Compensation for Injury
Payment or medical care provided if the participant is injured due to the study.
Confidentiality / Data Privacy
How personal and medical data is protected.
Consent Process / Informed Consent Form (ICF)
Involves learning and discussing the details of a clinical trial before deciding whether to take part. The ICF is not a contract, and if the person decides to join the trial, they can still withdraw at any time.
Control / Controlled
In a controlled clinical trial, a group (or groups) of participants will not be given the investigational drug. Instead they will be given a control - either an approved treatment for the condition or a placebo.
Double-Blind
A study where neither the participant nor the research staff knows who is receiving the investigational product or the placebo.
Ethics Committee
An independent team of people who review trial protocols to protect the rights and welfare of the people who take part.
European Medicines Agency (EMA)
An agency of the European Union (EU). The EMA protects public and animal health in EU member states and the countries of the European Economic Area.
Exclusion Criteria
Rules defining who cannot join the trial (e.g., specific co-existing illnesses).
Food and Drug Administration (FDA)
In the USA, the FDA is responsible for making sure medical treatments are safe and effective for people to use.
GCP (Good Clinical Practice)
An international quality standard for the design, conduct, recording and reporting of clinical trials. Ensures data and reported results are credible and accurate, and that participants' rights and confidentiality are protected.
How Well It WorksPlain English
Plain English alternative for "Efficacy."
Inclusion Criteria
Rules defining who can join the trial (e.g., age, specific disease diagnosis).
IND (Investigational New Drug)
A programme through which a pharmaceutical company obtains permission to ship an investigational drug across state lines before a marketing application has been approved.
Institutional Review Board (IRB)
An independent team of people who review studies to protect the rights and welfare of people who take part in clinical trials. Also referred to as IRB/EC (Ethics Committee).
Interventional
A type of clinical trial in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
Investigational Drug
A drug being tested in a trial.
Investigational Product (IP)
The drug, vaccine, or device being studied, which is not yet approved for public use.
Legally Authorized Representative (LAR)
An individual authorized under law to consent on behalf of a participant who cannot.
Open-Label
A study where both the researcher and participant know which treatment is being administered.
Patient Information Sheet (PIS)
A document provided to potential participants that explains the study in plain language - its purpose, procedures, risks, benefits and their rights.
Patient Organizations
Advocacy groups and patient organizations (also known as patient advocacy groups, or PAGs) support the needs of patients.
Phase
The stage of a clinical trial studying a drug or biological product, based on the study's objective, the number of participants, and other characteristics.
Placebo
An inactive substance that looks like the drug or treatment being tested. Comparing results from the two groups suggests whether changes in the test group result from the treatment or occur by chance.
Placebo Comparator Arm
An arm type in which a group of participants receives a placebo during a clinical trial.
Principal Investigator (PI)
The lead doctor responsible for the research team at a site.
Protocol
The written description of a clinical trial. It includes the trial's objectives, design, and methods. It may also include relevant scientific background and statistical information.
Randomization
A process of assigning participants to groups by chance, like flipping a coin.
Regulatory Authorities
Each country has its own regulatory authority with its own regulations, or laws, for conducting a clinical trial.
Risks and Discomforts
Potential side effects of the drug or discomforts from procedures.
Route of Administration
How the drug is given (e.g., IV, oral).
Screening / Pre-Study
Initial tests to check if the participant meets requirements.
Serious Adverse Event (SAE)
An adverse event that is fatal, life-threatening, or requires hospitalization.
Side EffectsPlain English
Plain English alternative for "Adverse Events."
Study DoctorPlain English
Plain English alternative for "Principal Investigator."
Study DrugPlain English
Plain English alternative for "Investigational Product."
Study Visits / Protocol Procedures
Specific tests, exams, or assessments performed during the trial (e.g., blood tests, imaging).
Subject / Participant
The individual taking part in the clinical trial.
Voluntary Participation
The decision to join is entirely the participant's choice, and they can leave without penalty.
Washout Period
A period in which a participant receives no treatment to clear previous medication from the system.
Withdrawal / Discontinuation
The right to leave the study at any time.
Why ICF Terminology Matters in Translation
Informed Consent Forms are among the most critical documents in clinical research. They are the primary mechanism through which a trial participant understands what they are consenting to - the procedures, risks, benefits, alternatives and their rights. A mistranslation or ambiguity in an ICF can invalidate informed consent, delay a clinical trial, or in the worst case, put a participant at risk.
The terminology listed above is not general medical vocabulary. These are terms with precise regulatory definitions under GCP (Good Clinical Practice) guidelines, and translators working on ICF documents must understand their exact meaning in context - not just their dictionary translation. For example, the distinction between an "Adverse Event" and a "Serious Adverse Event" has specific regulatory implications that must be preserved accurately in every target language.
At Semantics Trans Pvt Ltd., our pharmaceutical translators are specifically trained in ICF and clinical trial documentation. Every ICF translation goes through our triple-layer TEP process (Translation → Editing → Proofreading) by separate native-speaking professionals with pharmaceutical expertise. Back-translation is available for regulatory submissions requiring it.
Need an ICF or Pharmaceutical Translation?
Our pharmaceutical specialists handle ICF translations across all viable language pairs with the precision and regulatory awareness this content demands.